Review



human cscc cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    ATCC human cscc cell lines
    Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Human Cscc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 2187 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell lines/product/ATCC
    Average 98 stars, based on 2187 article reviews
    human cscc cell lines - by Bioz Stars, 2026-06
    98/100 stars

    Images

    1) Product Images from "Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel"

    Article Title: Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel

    Journal: Virology Journal

    doi: 10.1186/s12985-024-02502-y

    Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Figure Legend Snippet: Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001

    Techniques Used: Activity Assay, Derivative Assay, Infection, CCK-8 Assay, Control



    Similar Products

    human cscc cell lines  (ATCC)
    98
    ATCC human cscc cell lines
    Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Human Cscc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell lines/product/ATCC
    Average 98 stars, based on 1 article reviews
    human cscc cell lines - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier
    human cscc cell lines siha  (Procell Inc)
    86
    Procell Inc human cscc cell lines siha
    Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Human Cscc Cell Lines Siha, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell lines siha/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    human cscc cell lines siha - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    human cscc cell lines siha  (ATCC)
    98
    ATCC human cscc cell lines siha
    Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Human Cscc Cell Lines Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell lines siha/product/ATCC
    Average 98 stars, based on 1 article reviews
    human cscc cell lines siha - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier
    human cscc cell lines siha hpv positive  (ATCC)
    98
    ATCC human cscc cell lines siha hpv positive
    Oncolytic activity of CVB3/2035A in human <t>CSCC</t> cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice <t>bearing</t> <t>C33A,</t> SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
    Human Cscc Cell Lines Siha Hpv Positive, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell lines siha hpv positive/product/ATCC
    Average 98 stars, based on 1 article reviews
    human cscc cell lines siha hpv positive - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier
    human cscc cell line siha  (ATCC)
    98
    ATCC human cscc cell line siha
    Downregulation of SLC16A1-AS1 predicted poor survival of <t>CSCC</t> patients. ( A ) The expression of SLC16A1-AS1 in CSCC and paired non-tumor tissues from CSCC patients (n = 60) were determined by RT-qPCR. PCRs were performed in triplicate and mean values were presented and compared. *** p < 0.05. ( B ) The 60 patients were divided into high and low SLC16A1-AS1 level groups (n = 30, with median expression level of SLC16A1-AS1 in CSCC tissues as cutoff value) and survival curves were plotted.
    Human Cscc Cell Line Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cscc cell line siha/product/ATCC
    Average 98 stars, based on 1 article reviews
    human cscc cell line siha - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier
    cell culture human cscc cell line siha  (ATCC)
    98
    ATCC cell culture human cscc cell line siha
    Downregulation of SLC16A1-AS1 predicted poor survival of <t>CSCC</t> patients. ( A ) The expression of SLC16A1-AS1 in CSCC and paired non-tumor tissues from CSCC patients (n = 60) were determined by RT-qPCR. PCRs were performed in triplicate and mean values were presented and compared. *** p < 0.05. ( B ) The 60 patients were divided into high and low SLC16A1-AS1 level groups (n = 30, with median expression level of SLC16A1-AS1 in CSCC tissues as cutoff value) and survival curves were plotted.
    Cell Culture Human Cscc Cell Line Siha, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell culture human cscc cell line siha/product/ATCC
    Average 98 stars, based on 1 article reviews
    cell culture human cscc cell line siha - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001

    Journal: Virology Journal

    Article Title: Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel

    doi: 10.1186/s12985-024-02502-y

    Figure Lengend Snippet: Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001

    Article Snippet: Three human CSCC cell lines (C33A, SiHa, and CaSki) were purchased from the American Type Culture Collection (ATCC).

    Techniques: Activity Assay, Derivative Assay, Infection, CCK-8 Assay, Control

    Downregulation of SLC16A1-AS1 predicted poor survival of CSCC patients. ( A ) The expression of SLC16A1-AS1 in CSCC and paired non-tumor tissues from CSCC patients (n = 60) were determined by RT-qPCR. PCRs were performed in triplicate and mean values were presented and compared. *** p < 0.05. ( B ) The 60 patients were divided into high and low SLC16A1-AS1 level groups (n = 30, with median expression level of SLC16A1-AS1 in CSCC tissues as cutoff value) and survival curves were plotted.

    Journal: Cancer Management and Research

    Article Title: LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

    doi: 10.2147/CMAR.S276629

    Figure Lengend Snippet: Downregulation of SLC16A1-AS1 predicted poor survival of CSCC patients. ( A ) The expression of SLC16A1-AS1 in CSCC and paired non-tumor tissues from CSCC patients (n = 60) were determined by RT-qPCR. PCRs were performed in triplicate and mean values were presented and compared. *** p < 0.05. ( B ) The 60 patients were divided into high and low SLC16A1-AS1 level groups (n = 30, with median expression level of SLC16A1-AS1 in CSCC tissues as cutoff value) and survival curves were plotted.

    Article Snippet: Human CSCC cell line SiHa (ATCC, USA) was used.

    Techniques: Expressing, Quantitative RT-PCR

    SLC16A1-AS1 interacted with miR-194. ( A ) Schematic model of interaction between SLC16A1-AS1 and miR-194. ( B ) Luciferase reporter assay for luciferase activity of SLC16A1-AS1-reporter with mutated miR-194 binding sites in SiHa cells co-transfected with miR-194 mimics. n = 3. ** p < 0.01.

    Journal: Cancer Management and Research

    Article Title: LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

    doi: 10.2147/CMAR.S276629

    Figure Lengend Snippet: SLC16A1-AS1 interacted with miR-194. ( A ) Schematic model of interaction between SLC16A1-AS1 and miR-194. ( B ) Luciferase reporter assay for luciferase activity of SLC16A1-AS1-reporter with mutated miR-194 binding sites in SiHa cells co-transfected with miR-194 mimics. n = 3. ** p < 0.01.

    Article Snippet: Human CSCC cell line SiHa (ATCC, USA) was used.

    Techniques: Luciferase, Reporter Assay, Activity Assay, Binding Assay, Transfection

    Overexpression of SLC16A1-AS1 and miR-194 did not affect the expression of each other. ( A and B ) The effects of overexpression of SLC16A1-AS1 and miR-194 mimic transfection on SLC16A1-AS1 and miR-194 expression in siHa cells. n = 3. ( C and D ) The effects of SLC16A1-AS1 overexpression and miR-194 mimic transfection on miR-194 and SLC16A1-AS1 expression in SiHa cells. n = 3. Ns means the difference is not statistically significant. * p < 0.05.

    Journal: Cancer Management and Research

    Article Title: LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

    doi: 10.2147/CMAR.S276629

    Figure Lengend Snippet: Overexpression of SLC16A1-AS1 and miR-194 did not affect the expression of each other. ( A and B ) The effects of overexpression of SLC16A1-AS1 and miR-194 mimic transfection on SLC16A1-AS1 and miR-194 expression in siHa cells. n = 3. ( C and D ) The effects of SLC16A1-AS1 overexpression and miR-194 mimic transfection on miR-194 and SLC16A1-AS1 expression in SiHa cells. n = 3. Ns means the difference is not statistically significant. * p < 0.05.

    Article Snippet: Human CSCC cell line SiHa (ATCC, USA) was used.

    Techniques: Over Expression, Expressing, Transfection

    Overexpression of SLC16A1-AS1 led to upregulated SOCS2 through miR-194. ( A ) The expression of SOCS2 in CSCC and paired non-tumor tissues from CSCC patients were determined by RT-qPCR. ( B and C ) The effects of overexpression of SLC16A1-AS1 and miR-194 on the expression of SOCS2, which is a target of miR-194, were analyzed by RT-qPCR ( B ) and Western blot ( C ). n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Cancer Management and Research

    Article Title: LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

    doi: 10.2147/CMAR.S276629

    Figure Lengend Snippet: Overexpression of SLC16A1-AS1 led to upregulated SOCS2 through miR-194. ( A ) The expression of SOCS2 in CSCC and paired non-tumor tissues from CSCC patients were determined by RT-qPCR. ( B and C ) The effects of overexpression of SLC16A1-AS1 and miR-194 on the expression of SOCS2, which is a target of miR-194, were analyzed by RT-qPCR ( B ) and Western blot ( C ). n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Human CSCC cell line SiHa (ATCC, USA) was used.

    Techniques: Over Expression, Expressing, Quantitative RT-PCR, Western Blot

    SLC16A1-AS1 suppressed SiHa cell proliferation through the miR-194/SOCS2 axis. ( A – D ) Colony formation assay was performed to evaluate the effects of si-SLC16A1-AS1, miR-194 inhibitor and si-SOCS2 on the proliferation of SiHa cells. n = 3. ( E and F ) CCK-8 assay was used to detect the effects of si-SLC16A1-AS1, miR-194 inhibitor and si-SOCS2 on the proliferation of SiHa cells. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Cancer Management and Research

    Article Title: LncRNA SLC16A1-AS1 Suppresses Cell Proliferation in Cervical Squamous Cell Carcinoma (CSCC) Through the miR-194/SOCS2 Axis

    doi: 10.2147/CMAR.S276629

    Figure Lengend Snippet: SLC16A1-AS1 suppressed SiHa cell proliferation through the miR-194/SOCS2 axis. ( A – D ) Colony formation assay was performed to evaluate the effects of si-SLC16A1-AS1, miR-194 inhibitor and si-SOCS2 on the proliferation of SiHa cells. n = 3. ( E and F ) CCK-8 assay was used to detect the effects of si-SLC16A1-AS1, miR-194 inhibitor and si-SOCS2 on the proliferation of SiHa cells. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Human CSCC cell line SiHa (ATCC, USA) was used.

    Techniques: Colony Assay, CCK-8 Assay